Sun Shudong | Medicine | Best Researcher Award

Published on by China Scientist

Dr. Sun Shudong | Medicine| Best Researcher Award 

Dr. Shudong Sun is the Associate Chief Physician and Deputy Director of the Department of Burns and Wound Repair at Weifang People’s Hospital. He also serves as Deputy Director of the Weifang Burns Surgery Quality Control Center and is a Master’s Supervisor. A Senior Fellow of the European Wound Management Association (EWMA), Dr. Sun specializes in severe burn care, chronic wound treatment, and comprehensive scar management. His research focuses on burn-induced sepsis-related acute kidney injury and chronic refractory wound microenvironments. He leads multiple national and provincial research projects and holds several professional committee memberships. Dr. Sun has received numerous awards, including the Weifang Science and Technology Progress Award, and is recognized as a leading young medical talent in Shandong Province.

Dr. Sun Shudong | Shandong Second Medical University | China

Profile

🎓Education

  • Dr. Shudong Sun holds a Doctor of Medicine (MD) degree and has completed advanced specialized training in wound care. He is a Senior Fellow of the European Wound Management Association (EWMA) Advanced Wound Healing Program. His medical education and international training reflect a deep commitment to clinical excellence and academic advancement in the field of burns and wound repair.

👨‍🏫 Experience

  • Dr. Sun serves as the Associate Chief Physician and Deputy Director of the Department of Burns and Wound Repair at Weifang People’s Hospital. He also holds the role of Deputy Director of the Weifang Burns Surgery Quality Control Center. As a Master’s Supervisor, he is actively engaged in academic mentoring. Recognized as a Key Reserve Leader in Shandong Province’s Key Discipline in Burns and Plastic Surgery, Dr. Sun is a leading figure in his field. His selection for the Weifang Youth Medical Talent Support Program and recognition as an Excellent Trainee in the National Wound Healing Specialty Capability Training Program underscore his leadership and professional growth.

🤝 Awards and Recognition

  • Dr. Sun has received multiple accolades for his contributions to medicine and science. These include the Second Prize and two Third Prizes of the Weifang Science and Technology Progress Award, and the Second Prize in the Weifang Medical Science Popularization Contest. He was also named Excellent Lecturer by the Chinese Burn Surgery Association and won several case and paper competitions, such as the Excellent Case Award in the “Elite Cup” Case Competition and the Outstanding Work Award in the First National Youth Physician Burn Popular Science Competition. These honors reflect his clinical expertise, academic excellence, and dedication to public education.

💡Skills and Certifications

  • Dr. Sun has extensive clinical experience in the management of severe and critical burns, chemical and electrical injuries, and pediatric burn cases. He specializes in treating chronic refractory wounds such as radiation-induced skin injuries, diabetic foot ulcers, chronic lower limb ulcers, pressure ulcers, postoperative incision non-healing, and Fournier’s gangrene. He is also proficient in comprehensive scar management, offering early pharmaceutical interventions, sequential laser therapies, pressure treatment, and reconstructive surgery for complex hypertrophic and contracture scars across various body regions.

🔬 Research Focus

  • Dr. Sun’s research primarily focuses on the pathogenesis of acute kidney injury caused by burn-induced sepsis and the regulation of the microenvironment in chronic refractory wounds, as well as the application of innovative wound coverage materials. He leads and participates in several significant research projects, including the Shandong Medical Staff Science and Technology Innovation Plan, Shandong Natural Science Foundation, and Weifang Health Commission initiatives. His work integrates traditional Chinese medicine, modern clinical techniques, and biomedical innovation to improve outcomes in complex wound care.

🌎Conclusion

  • Dr. Shudong Sun’s combination of scientific excellence, clinical leadership, and sustained innovation makes him an outstanding candidate for the Research for Best Researcher Award. His work embodies the spirit of transformative research that leads to tangible medical breakthroughs. He is highly deserving of this recognition and sets a benchmark for future medical research professionals.

📖Publications

Title: Multi-functional nanofilms capable of angiogenesis, near-infrared-triggered anti-bacterial activity and inflammatory regulation for infected wound healing
Authors: Kun Wang, Yanqun Liu, Hui Wang, Yufang Liu, Xuelin Yang, Shudong Sun
Journal: Biomaterials Advances

Wei Liu | Clinical Medicine | Women Researcher Award

Published on by China Scientist

Prof. Wei Liu | Clinical Medicine | Women Researcher Award 

Dr. Wei Liu is a leading researcher and clinician specializing in geriatric cardiovascular medicine. He serves at both the Guangdong Provincial Geriatrics Institute, Guangdong Provincial People’s Hospital, and Shenzhen Baoan People’s Hospital. His research focuses on the molecular mechanisms underlying myocardial injury, cardiac fibrosis, and post-infarction remodeling, with emphasis on non-coding RNAs, RNA modifications, and inflammatory signaling pathways. Dr. Liu has published extensively in high-impact journals and plays a key role in advancing translational cardiology in aging populations.

Prof. Wei Liu | Shenzhen Baoan People’s Hospital | China

Profile

🎓Education

  • Wei Liu has received comprehensive medical and research training in cardiovascular and geriatric medicine. While the specific institutions and degrees are not listed in the publication data, his position as a corresponding author affiliated with prestigious institutes such as Guangdong Provincial People’s Hospital and Shenzhen Baoan People’s Hospital indicates advanced medical and research education, likely including an MD or PhD in cardiovascular medicine, immunology, or a related biomedical field. His research maturity suggests postdoctoral training or equivalent experience in molecular cardiology or cardiovascular immunopathology.

👨‍🏫 Experience

  • Dr. Wei Liu currently serves in dual capacities within major Chinese medical institutions. He is a senior physician and researcher at the Department of Geriatric Cardiovascular Division, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People’s Hospital, under the Guangdong Academy of Medical Sciences in Guangzhou. Additionally, he holds a position in the Department of Geriatric Medicine at Shenzhen Baoan People’s Hospital in Shenzhen. These roles reflect his leadership in clinical cardiology and translational research, especially focusing on aging populations and chronic cardiac conditions. His work integrates clinical care, molecular biology, and cardiovascular pathology.

🤝 Awards and Recognition

  • Dr. Liu’s role as a corresponding author in internationally peer-reviewed journals such as Biochimica et Biophysica Acta – Molecular Basis of Disease, Molecular Immunology, and Current Molecular Pharmacology indicates significant recognition within the cardiovascular research community. His multiple first and corresponding author publications in 2024 and 2025 imply active leadership in funded projects and recognition by research institutions, potentially including provincial or national medical research grants and academic honors.

💡Skills and Certifications

  • Dr. Liu possesses a multidisciplinary skill set combining clinical geriatric cardiology, molecular pharmacology, and immunopathology. His expertise includes in vivo cardiac modeling, myocardial infarction studies, regulatory RNA biology, inflammation signaling, and translational pharmacotherapy. He is proficient in experimental techniques involving gene expression regulation, immune cell signaling, and therapeutic intervention evaluations. His collaborative publications suggest strong skills in interdisciplinary research, experimental design, and scientific writing.

🔬 Research Focus

  • Dr. Liu’s research centers on the molecular mechanisms of cardiovascular disease, particularly myocardial fibrosis, cardiac hypertrophy, and myocardial injury related to inflammation and autoimmune responses. He investigates post-infarction remodeling processes, with emphasis on non-coding RNAs such as tRNA-derived fragments (tsRNAs), RNA modifications like ac4C and m5C, and associated regulatory proteins such as NAT10 and Alyref. His studies also explore cardioprotective pharmacological agents like artemisinin and ivabradine and their effects on signaling pathways including TGF-β1/Smad, ERK1/2, p38 MAPK, and JAK2/STAT3. This positions him at the forefront of translational cardiovascular research in China.

🌎Conclusion

  • Dr. Wei Liu exemplifies the qualities celebrated by the Research for Women Researcher Award—scientific excellence, clinical impact, and leadership in a critical area of healthcare. Her prolific research, academic leadership, and commitment to translational medicine make her a standout candidate. Recognizing her achievements through this award would not only honor her individual contributions but also inspire broader representation and advancement of women in medical science.

📖Publications

  • Title: tRNA-derived small RNA (tsr007330) regulates myocardial fibrosis after myocardial infarction through NAT10-mediated ac4C acetylation of EGR3 mRNA
    Author: Hao Y, Li B, Yin F, Liu W*
    Journal: Biochimica et Biophysica Acta – Molecular Basis of Disease, 2024

  • Title: IFITM3 mediates inflammation induced myocardial injury through JAK2/STAT3 signaling pathway
    Author: Xiong C, Li B, Song R, Ma Z, Huber SA, Liu W*
    Journal: Molecular Immunology, 2024

  • Title: Artemisinin attenuates isoproterenol-induced cardiac hypertrophy via the ERK1/2 and p38 MAPK signaling pathways
    Author: Song RX, Xiong CM, Bai JC, Bai ZZ, Liu W*
    Journal: Current Molecular Pharmacology, 2024

  • Title: Ivabradine alleviates experimental autoimmune myocarditis-mediated myocardial injury
    Author: Zhu M, Lu J, Li X, An Y, Li B, Liu W*
    Journal: International Heart Journal, 2024

  • Title: The m5C reader Alyref is involved in the regulation of cardiac remodeling after myocardial infarction through the synthesis of extracellular matrix proteins in cardiac fibroblasts
    Author: Hao Y, Li B, Tian WD, Yin F, Liu W*
    Journal: Biochimica et Biophysica Acta – Molecular Basis of Disease, 2025

Qi Feng | Internal Medicine | Best Researcher Award

Published on by China Scientist

Assoc. Prof. Dr. Qi Feng | Internal Medicine  | Best Researcher Award

Qi Feng is an Associate Professor at the Research Institute of Nephrology, The First Affiliated Hospital of Zhengzhou University. He received his PhD in Chemical Biology from Osaka University, and holds master’s and bachelor’s degrees from Jilin University and Henan University of Science and Technology, respectively. His research focuses on diabetic nephropathy, renal pharmacology, immunology, ferroptosis, and metabolism. With postdoctoral experience in Japan and an H-index of 19, he is an active contributor to nephrology and biomedical research.

Assoc. Prof. Dr. Qi Feng | The First Affiliated Hospital of Zhengzhou University | China

Profile

SCOPUS ID

🎓Education

  • Qi Feng earned his Doctor of Science degree in Chemical Biology from Osaka University in Japan, where he conducted research under the guidance of Professor Koichi Fukase from 2014 to 2017. Prior to that, he completed his Master of Science in Bioengineering at Jilin University, China, from 2011 to 2014 under the supervision of Professor Yuxin Chen. He began his academic journey with a Bachelor of Science in Biotechnology at Henan University of Science and Technology, China, graduating in 2011.

👨‍🏫 Experience

  • Qi Feng is currently serving as an Associate Professor at the Research Institute of Nephrology, The First Affiliated Hospital of Zhengzhou University, China, a position he has held since January 2025. Before this role, he worked as an Assistant Professor at the same institute from August 2018 to December 2024. His international experience includes a postdoctoral fellowship at Osaka University in Japan from September 2017 to March 2018.

🏆Awards and Recognitions

  • With an H-index of 19 and an active academic profile on ResearchGate, Qi Feng has established himself as a respected researcher in nephrology and biomedical sciences. He has made significant contributions to the understanding of diabetic nephropathy and continues to publish high-impact studies in this field.

💡Skills and Certifications

  • Qi Feng is skilled in molecular biology, pharmacological research, and immunological techniques. His expertise spans both in vitro and in vivo models, and he has a strong foundation in scientific collaboration, data analysis, and academic publishing. His interdisciplinary training and international research experience make him a valuable contributor to the global scientific community.

🔬 Research Focus

  • Qi Feng’s research centers on the pathophysiology and treatment of diabetic nephropathy, with broader interests in renal pharmacology, immunology, ferroptosis, and metabolic disorders. His interdisciplinary approach integrates chemical biology, bioengineering, and translational medicine to uncover new therapeutic targets and strategies for kidney-related diseases.

🌎Conclusion

  • Dr. Qi Feng stands out as a remarkably suitable candidate for the Best Researcher Award. His research excellence, forward-thinking contributions, and dedication to advancing internal medicine and nephrology position him at the forefront of medical science. Awarding Dr. Feng would not only recognize his achievements but also inspire continued innovation in tackling kidney-related diseases.

📖Publications

  • Title: Lactate and Lactylation in AKI‐to‐CKD: Epigenetic Regulation and Therapeutic Opportunities
    Authors: Yi Hou, Dongwei Liu, Zuishuang Guo, Cien Wei, Fengyu Cao, Yue Xu, Qi Feng, Fengxun Liu
    Year: 2025
    Journal: Cell Proliferation

  • Title: Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways
    Authors: Qi Feng, Xiaoyue Yu, Junwei Xie, Fengxun Liu, Xiaonan Zhang, Shiyang Li, Yixue Wang, Shaokang Pan, Dongwei Liu, Zhangsuo Liu
    Year: 2025
    Journal: Phytomedicine

  • Title: RNA 5-Methylcytosine Modification: Regulatory Molecules, Biological Functions, and Human Diseases
    Authors: Yanfang Lu, Liu Yang, Qi Feng, Yong Liu, Xiaohui Sun, Dongwei Liu, Long Qiao, Zhangsuo Liu, Chengqi Yi
    Year: 2024
    Journal: Genomics, Proteomics & Bioinformatics

  • Title: Mitochondria-associated endoplasmic reticulum membrane (MAM): a dark horse for diabetic cardiomyopathy treatment
    Authors: Yong Liu, Jin-Ling Huo, Kaidi Ren, Shaokang Pan, Hengdao Liu, Yifeng Zheng, Jingfang Chen, Yingjin Qiao, Yang Yang, Qi Feng
    Year: 2024
    Journal: Cell Death Discovery

  • Title: Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities
    Authors: Jia Li, Jiayu Duan, Chaoyang Hua, Shaokang Pan, Guangpu Li, Qi Feng, Dongwei Liu, Zhangsuo Liu
    Year: 2024
    Journal: Burns & Trauma

Dr. shuwei shen | Biomedical engineering | Best Researcher Award | 1176

Published on by China Scientist

Dr. shuwei shen | Biomedical engineering | Best Researcher Award

Dr. shuwei shen , University of Science and Technology of China, China

Extensive Research Experience

His focus on the standardization of medical devices and intelligent diagnosis using deep learning demonstrates a significant impact in the medical and technological fields.

Innovative Contributions

With over 30 papers in prestigious journals and more than 20 patents, his work reflects high-level innovation and contributions to the field.

 Profile

Scopus

Google Scholar

📚 Early Academic Pursuits

Dr. Shuwei Shen earned his Ph.D. from the University of Science and Technology of China in 2019. During his doctoral studies, he developed a strong foundation in medical device standardization and intelligent diagnosis and treatment methods, focusing on the application of deep learning techniques.

💼 Professional Endeavors

From 2019 to 2021, Dr. Shen conducted postdoctoral research at the First Affiliated Hospital of the University of Science and Technology of China. This postdoctoral tenure allowed him to delve deeper into the practical applications of his research, bridging the gap between theoretical studies and real-world medical challenges. Since 2021, he has been serving as an Associate Researcher at the Suzhou Institute for Advanced Research, University of Science and Technology of China.

🔬CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Shen’s research primarily focuses on the standardization of medical devices using tissue phantoms and the development of intelligent diagnosis and treatment systems through deep learning. His completed and ongoing research projects include the development of intelligent diagnostic systems for skin diseases and the creation of a research and preparation system for tissue oxygenation biomimetic models.

🌟Impact and Influence

  • Dr. Shen has made significant contributions to the field of medical devices and intelligent diagnosis. He has published over 30 papers in prestigious journals, such as IEEE Transactions on Medical Imaging, Biomedical Optics Express, Chemical Engineering Journal, and IEEE Journal of Biomedical and Health Informatics. His work has been widely recognized and cited, contributing to his citation index of 10 (h-index). Additionally, he has applied for more than 20 patents, reflecting the innovative nature of his research.

📖 ACADEMIC CITES

Dr. Shen’s extensive publication record includes 278 articles indexed in Scopus, showcasing the breadth and depth of his research. His prolific output highlights his dedication to advancing the fields of tissue phantoms, 3D printing, intelligent diagnosis and treatment, and advanced drug delivery systems.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Dr. Shen aims to continue pushing the boundaries of medical device innovation and intelligent diagnostic systems. His ongoing research and future projects are expected to further enhance the standardization and effectiveness of medical treatments, improving patient outcomes and advancing the field of medical technology.

📰PUBLICATIONS

  • Single model deep learning on imbalanced small datasets for skin lesion classification
    • Authors: P. Yao, S. Shen, M. Xu, P. Liu, F. Zhang, J. Xing, P. Shao, B. Kaffenberger, …
    • Journal: IEEE Transactions on Medical Imaging
  • A low-cost high-performance data augmentation for deep learning-based skin lesion classification
    • Authors: S. Shen, M. Xu, F. Zhang, P. Shao, H. Liu, L. Xu, C. Zhang, P. Liu, P. Yao, …
    • Journal: BME Frontiers
  • A single model deep learning approach for Alzheimer’s disease diagnosis
    • Authors: F. Zhang, B. Pan, P. Shao, P. Liu, S. Shen, P. Yao, RX Xu, …
    • Journal: Neuroscience
  • Freeform fabrication of tissue-simulating phantom for potential use of surgical planning in conjoined twins separation surgery
    • Authors: S. Shen, H. Wang, Y. Xue, L. Yuan, X. Zhou, Z. Zhao, E. Dong, B. Liu, W. Liu, …
    • Journal: Scientific Reports
  • Fabrication of a multilayer tissue-mimicking phantom with tunable optical properties to simulate vascular oxygenation and perfusion for optical imaging technology
    • Authors: G. Liu, K. Huang, Q. Jia, S. Liu, S. Shen, J. Li, E. Dong, P. Lemaillet, DW Allen, …
    • Journal: Applied Optics

Prof Dr. Qingchun Zeng | Calcific Aortic Valve Disease | Best Researcher Award | 1131

Published on by China Scientist

Prof.Dr Qingchun Zeng | Calcific Aortic Valve Disease |  Best Researcher Award

Prof Dr. Qingchun Zeng , Southern Medical University, China

Professional Profile

Scopus

Academic and Professional Background 📘

Dr. Zeng Qingchun has dedicated his career to understanding and combating the pathogenesis, prevention, and treatment of calcific aortic valve disease (CAVD) and heart failure. His research delves into the role of immune regulation in these conditions, exploring the molecular pharmacological effects and mechanisms. He has pioneered several fundamental theories on the involvement of intestinal flora and metabolites in the pathogenesis of CAVD.

 Research and Innovations 🧪📊

  • Completed/Ongoing Research Projects: Dr. Zeng has spearheaded numerous research projects, including four funded by the National Natural Science Foundation (Project Nos: 82270374, 82070403, B17703BG, 815703SZ).
  • Citation Index: Scopus Profile
  • Consultancy/Industry Projects: None

Publications📖

Dr. Zeng has published 295 articles in prominent journals. Notable publications include:

  1. Xiang G, Huang R, Xie M, Zhao H, Xu X, Chen Y, Ren H, Nu D, Feng B. Non-coding RNA regulates the expression of KRM1 and DKK1 to synergistically affect aortic valve lesions. Exp Mol Med. 2024. DOI: 10.1038/s12276-024-01256-5
  2. Zhong G, Su S, Li J, Zhao H, Hu D, Chen J, Li S, Lin Y, Wen L, Lin X, Xiang G, Xu D, Zeng Q. Activation of Piezo1 promotes osteogenic differentiation of aortic valve interstitial cells through YAP-dependent mechanotransduction. Sci Adv. 2023. DOI: 10.1126/sciadv.adg0478
  3. Li S, Luo Z, Su S, Lin L, Xiang G, Zhao J, Xu X, Xu D, Zeng Q. Targeted inhibition of PTPN22 alleviates osteogenic responses in aortic valve interstitial cells and lesions in mice. BMC Med. 2023. DOI: 10.1186/s12916-023-02888-6
  4. Peng X, Su S, Zeng J, Xie K, Yang X, Xiang G, Xiao Z, Zhu P, Zeng S, Xu D, Zeng Q. 4-Octyl itaconate suppresses osteogenic response in aortic valvular interstitial cells via the JAK2/STAT3 pathway. Free Radic Biol Med. 2022. DOI: 10.1016/j.freeradbiomed.2022.06.246
  5. Meng Q, Liu C, Ao L, Cleveland JC Jr, Song R, Xu D, Fullerton DA, Meng X. Cross-talk between the TLR4 and Notch1 pathways augments the inflammatory response in the interstitial cells of stenotic human aortic valves. Circulation. 2012. DOI: 10.1161/CIRCULATIONAHA.111.083675

 Editorial Appointments📝

  • Cardiovascular Innovation and Applications, Editorial Board Member
  • Frontiers in Cell and Developmental Biology, Guest Editor
  • Frontiers in Cardiovascular Medicine, Senior Editor
  • Journal of Molecular and Cellular Cardiology, Editorial Board Member

Collaborations 🤝

Dr. Zeng leads international defense and technology cooperation projects in Guangdong Province, including research on the mechanisms by which Hesperetin prevents cardiovascular disease and mitigates mitochondrial damage.

Professional Memberships 🏅

  • Standing Committee, Heart Failure Committee of Guangdong Medical Association
  • Member, Atherosclerosis Professional Committee of Chinese Pathophysiological Society
  • Member, China Branch of the International Atherosclerosis Society
  • Member, Expert Committee of the Heart Failure Specialist Medical Association

Areas of Research 🔬

  • Calcific Aortic Valve Disease
  • Heart Failure

Contributions🌟

Dr. Zeng’s extensive research, published in top-tier international journals, has significantly advanced understanding of the increasing incidence and pathogenesis of CAVD. His clinical studies and data analyses provide crucial evidence for transcatheter treatments, antithrombotic programs, and prognosis assessment, thereby enhancing clinical diagnosis and treatment of CAVD.

NOTABLE PUBLICATIONS
    • α-Ketoglutarate improves cardiac insufficiency through NAD+-SIRT1 signaling-mediated mitophagy and ferroptosis in pressure overload-induced mice
      • Journal: Molecular Medicine
      • Authors: Yu, H., Gan, D., Luo, Z., Xu, D., Ren, H.
      • Year: 2024
      • Citations: 4
    • Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT
      • Journal: Chinese Medical Journal
      • Authors: Lin, Y., Zhao, H., Hu, D., Xu, D., Zeng, Q.
      • Year: 2024
      • Citations: 0
    • Association between Methylmalonic Acid and Abdominal Aortic Calcification in Adults: A Cross-Sectional Study
      • Journal: Cardiovascular Innovations and Applications
      • Authors: Chen, J., Lin, Y., Teng, Z., Li, J., Zeng, Q.
      • Year: 2024
      • Citations: 0
    • Targeted inhibition of PTPN22 is a novel approach to alleviate osteogenic responses in aortic valve interstitial cells and aortic valve lesions in mice
      • Journal: BMC Medicine
      • Authors: Li, S., Luo, Z., Su, S., Xu, D., Zeng, Q.
      • Year: 2023
      • Citations: 1
    • Association between urinary biomarkers of polycyclic aromatic hydrocarbons and severe abdominal aortic calcification in adults: data from the National Health and Examination Nutrition Survey
      • Journal: BMC Cardiovascular Disorders
      • Authors: Yang, X., Zhou, H., Zhang, H., Xu, D., Zeng, Q.
      • Year: 2023
      • Citations: 3